Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab with Chemo-Radiation in Head and Neck Cancer
NCT00401401Phase 2Terminated
- Sponsor
- Genmab
- Start
- Dec 2006
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of zalutumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Genmab. Started Dec 2006; status: terminated.
02
Drugs
zalutumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00401401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401401.